Gastrointestinal Cancer

Official Title: PHASE II/III SECOND-LINE NABPLAGEM VS. NAB-PACLITAXEL/GEMCITABINE IN BRCA1/2 OR PALB2 MUTANT METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PLATINUM)

Study Purpose: To evaluate and compare overall response rate (ORR) in patients with BRCA1/2 or PALB2 mutant pancreas cancer whose disease has progressed on front-line FOLFIRINOX treated with NABPLAGEM = nab-paclitaxel, gemcitabine, and cisplatin (arm 1) versus nab-paclitaxel and gemcitabine (arm 2)

Status: Recruiting

Official Title: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Study Purpose: To see if treating with olaparib compared to the usual approach which is observation,  is more successful in preventing pancreatic cancer from coming back 

Status: Recruiting

Official Title: Testing Combination Chemotherapy with or without an Investigational Drug or the Investigational Drug Alone for Metastatic Colon or Rectal Cancer

Study Purpose: To learn if adding the experimental agent atezolizumab (MPDL3280A) to the usual treatment or giving the experimental agent alone is better than the usual treatment alone for metastatic colon or rectal cancer.

Status: Suspended

Official Title: A testing the addition of pembrolizumab, an immunotherapy cancer drug to olaparib alone as therapy for patients with pancreatic cancer that has spread with unhealthy tumor suppressor genes.

Study Purpose: To compare the usual treatment alone to using pembrolizumab plus the usual treatment.

Status: Recruiting